IFN-?: A novel therapeutic for treatment of COVID-19

Navn på bevillingshaver

Rune Hartmann


Aarhus University


DKK 188,804




Research Infrastructure


Despite impressive progress over the past 10 months, there is still an urgent need for developing novel therapeutics against the SARS2 virus, the causative agent of Covid19. IFN-λ has already shown promising results in phase 2 clinical trials. To help doctors decide when and how IFN-λ should potentially be used to treat COVID-19 patients, we need more knowledge about the efficacy of IFN-λ and how IFN-λ affects the inflammatory response in the context of SARS2 infection in vivo. The golden Syrian hamster, is susceptible to infection with SARS2 and replicate human disease, thus this is a promising small animal model. We suggest producing recombinant hamster IFN-λ to study its effect against SARS-CoV-2 infection in the hamser model.

Tilbage til oversigtssiden